Cut In Australia Drug Support Leads Seniors To Trim Use
This article was originally published in PharmAsia News
A recent move by the Australian government to cut its share of the cost of drugs for retirees has led many to cut back on their medicines by an average of 11 percent. Some have stopped taking life-saving drugs, according to a study of the impact of the government move. The report says the biggest decline in drug use among the group was among those with asthma, blood-clot risks, osteoporosis and ulcers. A federal funding cut had a similar impact three years ago on the use of anti-cholesterol drugs. The price of some drugs for seniors increased by 90 percent after the federal-support reduction. (Click here for more
You may also be interested in...
Lead immuno-oncology asset NC318 targeting Siglec-15 showed encouraging early activity in patients refractory to PD-1/L1 inhibitors, but now Phase II plans are scuttled in lung and ovarian cancers.
Pataday Once Daily Relief Extra Strength is the same formulation as Novartis' Rx Pazeo. It will be the first OTC eye drop indicated for allergy itch with 24-hour efficacy, available online in September and through retailers in early 2021.
Bristol makes its own deal with Celgene ally Dragonfly, while Gilead ends virology partnerships with Durect and Precision BioSciences.